Phase I Clinical Testing Antimalarial Drugs.
Abstract
The safety and tolerance of mefloquine 500 mg weekly over 52 weeks was determined in a study involving 50 subjects. A comprehensive study of the pharmacokinetics of mefloquine was also undertaken. Mefloquine methanesulfonate was shown to be unsafe when administered parenterally because of local tissue irritation. A concomitant decrease in serum haptoglobin was noted with infusion of this drug which is at present unexplained. A pharmacokinetics study of WR 184,806.H3PO4 (involving 20 subjects) was completed. A study to evaluate the gastrointestinal absorption kinetics of WR 30090 (oleic acid) was started but suspended pending the resolution of difficulties with the drug assay. A study to compare the bioavailability of the Walter Reed and Hoffmann-LaRoche formulations of mefloquine hydrochloride has just been completed. (Author)
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 1978
- Accession Number
- ADA058221
Entities
People
- Richard C. Reba